ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor-specific T cells by acting in the tumor microenvironment and draining lymph nodes

ANV600 - Anaveon

Keytruda (pembrolizumab) - Merck (MSD)

https://dx.doi.org/10.1136/jitc-2024-SITC2024.0954

Patrizia Murer; Anais Zurbach; Laetitia Petersen; Nicole Egli; Andreas Katopodis; Christoph Huber

Oct 4, 2024